Zika Virus Testing Market Upcoming Challenges, Insight And Global Outlook 2031

The global zika virus testing market experienced a moderate incline, experiencing a CAGR of just above 2% between 2017 and 2020, being valued at a little over US$ 4 billion, as per ESOMAR-certified firm Future Market Insights (FMI) latest report on the landscape. Growth was majorly underpinned by the introduction of numerous point-of-care powerful testing approaches to facilitate timely detection of the virus.

According to FMI’s analysis, clinicians have been exhibiting a high preference towards enzyme linked immunosorbent assay (ELISA) tests. Compared to other immunoassay methods, ELISA tests are more accurate, are considered highly sensitive, specific and compare favorably with other methods used to detect substances in the body, such as radioimmune assay (RIA) tests.

Prominent players are experiencing immense growth opportunities across tropical regions, attributed to the high concentration rate of the zika virus across such regions as the Caribbean, Central America, Africa and the Asian sub-continent. Players such as EUROIMMUN have emerged at the forefront, being the first diagnostics company to provide a testing approach to detect the zika virus. Its product lines include the Anti-Zika Virus ELISA (IgA or IgG or IgM or IgAM) fully automatable test and the IIFT Arbovirus Fever Mosaic 2 (IgG or IgM) test.

Get Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2913

Key Takeaways from FMI’s Zika Virus Testing Market Study

  • By test type, ELISA-based zika virus testing surpassed US$ 4 billion until 2020
  • By end-user, private commercial laboratories to remain primary point of contact for availing zika virus testing
  • Multiple regulatory approvals for various testing approaches by the FDA to bolster US zika virus testing market growth
  • Brazil to attract major zika virus testing providers amid increasing governmental initiatives to contain its spread
  • Growing focus on pregnant women’s health to accelerate testing volumes in Puerto Rico
  • UK to experience limited uptake amid the non-notifiable nature of the disease due to limited outbreaks

“Rising government initiatives to address possible suspected infection cases are providing a wide platform for the introduction of advanced zika virus testing approaches, providing key players a chance to expand their footprints across key geographies,” says the FMI analyst.  

Competitive Landscape

Prominent zika virus testing manufacturers are reliant on offering advanced testing approaches in order to yield quicker results so as to facilitate timely treatment. Besides, key research laboratories and organizations also emphasize on expanding their testing capabilities by virtue of strategic acquisition and collaboration agreements.

In 2017, the US FDA issued an Emergency Use Authorization (EUA) to authorize the RealStar® Zika Virus RT-PCR Kit for the in vitro qualitative detection of Zika virus with specified instruments. This test is offered by Altona Diagnostics GmbH, and tests presence of the virus in human serum, EDTA plasma and/or urine.

Similarly, ARUP Laboratories offers both serology and RT-PCR tests for detecting the zika virus. The former is called the Zika Virus IgM Antibody Capture (MAC) based on the ELISA technique. In the latter case, the test is conducted by collecting patients’ blood or urine samples.

More Insights on the Global Zika Virus Testing Market

In its latest report, FMI offers an unbiased analysis of the global zika virus testing market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of test type (rapid IgG/IgM test and ELISA test) and end-user (hospitals & clinics, private commercial laboratories and government/publicly funded programs) across six regions (North America & Europe, Latin America, Central America, Caribbean, South East Asia and Rest of the World).  

Any Queries, Contact us @ https://www.futuremarketinsights.com/ask-question/rep-gb-2913

Key questions answered in the report

  • How will the zika virus testing market expand in the long-run?

The global zika virus testing market is set to register credible gains through 2021 and beyond, registering a multi-billion dollar valuation amid extensive research and development to incorporate highly advanced diagnostic approaches which will help in timely detection and diagnosis of the virus

  • Which region is likely to emerge as the most lucrative zika virus testing hub?

As per FMI’s report, bulk of all zika virus testing is expected to occur across the tropical regions of the world, such as the Asian sub-continent, Caribbean and Central America respectively

  • Which is the most prominent zika virus testing treatment approach by test type?

ELISA based zika virus testing treatment will likely remain the most preferred approach in forthcoming years due to its immense promises in terms of higher accuracy and efficacy

  • Which prominent players operate within the zika virus testing landscape?

EUROIMMUN US Inc., Creative Diagnostics, Quest Diagnostics, Artron Laboratories Inc., RapiGEN Inc., GenBody Inc., JAJ International Inc., LumiQuick Diagnostics Inc., Biocan Diagnostics Inc., NECTAR LIFESCIENCES LTD., Luminex Corporation, ARUP Laboratories, Abbott Molecular Inc., Hologic and Vela Diagnostics are some prominent regenerative medicine players profiled by FMI’s report

Leave a comment

Your email address will not be published. Required fields are marked *